

JUL 28 1998



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Stephen F. Weinstock
Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-3500

In Re: Patent Term Extension
Application for
U.S. Patent No. 4,873,259

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,873,259, which claims the human drug product ZYFLO™ (zileuton), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 1,398 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue a certificate of extension, under seal, for a period of 1,398 days.

The period of extension has been calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of July 18, 1997 (62 Fed. Reg. 38562). Under 35 U.S.C. § 156(c):

$$\begin{aligned}\text{Period of Extension} &= \frac{1}{2} (\text{Testing Phase}) + \text{Approval Phase} \\ &= \frac{1}{2} (2,454 - 710) + 875 \\ &= 1,747 \text{ days}\end{aligned}$$

Since the regulatory review period began October 31, 1987, before the patent issued (October 10, 1989), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). (From October 31, 1987 to October 10, 1989 is 710 days; this period is subtracted for the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory review period: $2,454 - 710 = 1,744$ days.) No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the 14 year exception of 35 U.S.C. § 156(c)(3) operates to limit the term of the extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product plus any patent term extension cannot exceed fourteen years. The period of extension calculated above, 1,747 days, would extend the patent from February 10, 2007 (35 U.S.C. § 154) to December 9, 2010, which is beyond the 14-year limit (the approval date is December 9, 1996, thus the 14 year limit is December 9, 2010). The period of extension is thus limited to December 9, 2010, by operation of 35 U.S.C.

§ 156(c)(3). Accordingly, the period of extension is the number of days to extend the term of the patent from its original expiration date, February 10, 2007, to and including December 9, 2010, or 1,398 days.

The limitations of 35 U.S.C. § 156(g)(6) do not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:	4,873,259
Granted:	October 10, 1989
Original Expiration Date ¹ :	February 10, 2007
Applicant:	James B. Summers et al.
Owner of Record:	Abbott Laboratories
Title:	Indole Benzofuran, Benzothiophene Containing Lipoxygenase Inhibiting Compounds
Classification:	514/433
Product Trade Name:	ZYFLO™ (zileuton)
Term Extended:	1,398 days
Expiration Date:	December 9, 2010


Any correspondence with respect to this matter should be addressed as follows:

By mail: Assistant Commissioner for Patents
Box Patent Ext.
Washington, D.C. 20231

By FAX: (703) 308-6916
Attn: Special Program Law Office

¹Subject to the provisions of 35 U.S.C. § 41(b).

Telephone inquiries related to this determination should be directed to the undersigned at (703) 306-3159.



Karin Tyson
Senior Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: ZYFLO™ (zileuton)
FDA Docket No.: 97E-0067